Multiple Dose, Steady State-Partial reference replicate [Design Issues]

posted by jag009  – NJ, 2018-07-17 08:34 (2550 d 12:59 ago) – Posting: # 19074
Views: 4,854

❝ Please help in understanding whether it is possible to conduct “An open-label, randomized, Multiple Dose, Steady State, two treatments, three periods, three sequence, three way, Reference Replicated crossover bioequivalence study” for USFDA Submission?


Why you are doing multiple dose? FDA does not like multiple dose (unless you are doing b2).

J

Complete thread:

UA Flag
Activity
 Admin contact
23,430 posts in 4,931 threads, 1,677 registered users;
57 visitors (0 registered, 57 guests [including 12 identified bots]).
Forum time: 21:33 CEST (Europe/Vienna)

To know that we know what we know,
and to know that we do not know what we do not know,
that is true knowledge.    Nicolaus Copernicus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5